Raymond James Has Weak Estimate for TSE:ONC FY2024 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at Raymond James reduced their FY2024 earnings per share (EPS) estimates for Oncolytics Biotech in a report released on Tuesday, November 12th. Raymond James analyst R. Sarugaser now anticipates that the company will earn ($0.44) per share for the year, down from their previous forecast of ($0.38). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Stock Performance

ONC opened at C$1.38 on Friday. Oncolytics Biotech has a 52-week low of C$1.15 and a 52-week high of C$2.32. The firm has a market capitalization of C$106.07 million, a PE ratio of -3.63 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The business’s 50-day simple moving average is C$1.50 and its 200 day simple moving average is C$1.45.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.